LX-9211 is a small molecule commercialized by Lexicon Pharmaceuticals, with a leading Phase II program in Diabetic Neuropathic Pain. According to Globaldata, it is involved in 6 clinical trials, of which 5 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of LX-9211’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for LX-9211 is expected to reach an annual total of $26 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

LX-9211 Overview

LX-9211 (BMS-986176) is under development for the treatment of diabetic peripheral neuropathic pain and postherpetic neuralgia. The drug candidate is administered through oral route as tablets. The drug candidate targets AP2 associated kinase 1 (AAK1).

Lexicon Pharmaceuticals Overview

Lexicon Pharmaceuticals (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. Lexicon is focusing on the introduction of its approved medication, Inpefa (sotagliflozin), into the market specifically for the treatment of heart failure. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin for hypertrophic cardiomyopathy (HCM) and type 1 diabetes. Its clinical and preclinical development programs, LX9211, are meant for the treatment of diabetes and neuropathic pain, respectively. It has business collaborations with several pharmaceutical and biotechnology companies. The company operates an office in New Jersey and has a laboratory in Texas. Lexicon is headquartered at The Woodlands, Texas, the US.
The company reported revenues of (US Dollars) US$1.2 million for the fiscal year ended December 2023 (FY2023), compared to a revenue of US$0.1 million in FY2022. The operating loss of the company was US$171.8 million in FY2023, compared to an operating loss of US$100.8 million in FY2022. The net loss of the company was US$177.1 million in FY2023, compared to a net loss of US$101.9 million in FY2022. The company reported revenues of US$1.1 million for the first quarter ended March 2024, an increase of 61% over the previous quarter.

For a complete picture of LX-9211’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.